ストックスクリーナーアプリを入手
7.18
3.46%
0.24
アフターアワーズ：
7.16
-0.02
-0.28%
前日終値:
$6.94
開ける：
$7.11
24時間の取引高:
100.53K
Relative Volume:
0.98
時価総額：
$655.63M
収益：
$116.59M
当期純損益:
$9.88M
株価収益率:
319.11
EPS:
0.0225
ネットキャッシュフロー:
$-2.40M
1週間 パフォーマンス:
+2.43%
1か月 パフォーマンス:
-16.99%
6か月 パフォーマンス:
-1.51%
1年 パフォーマンス:
-24.34%
1日の値動き範囲:
$7.10
$7.34
1週間の範囲:
$6.58
$7.34
52週間の値動き範囲:
$6.11
$11.78
Gyre Therapeutics Inc Stock (GYRE) Company Profile
名前
Gyre Therapeutics Inc
セクター
電話
(858) 567-7770
住所
12770 HIGH BLUFF DRIVE, SAN DIEGO
Compare GYRE vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GYRE
Gyre Therapeutics Inc
|
7.18 | 633.72M | 116.59M | 9.88M | -2.40M | 0.0225 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Gyre Therapeutics Inc Stock (GYRE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-10 | 開始されました | Jefferies | Buy |
| 2025-08-26 | 開始されました | H.C. Wainwright | Buy |
| 2025-03-11 | 開始されました | Noble Capital Markets | Outperform |
| 2021-04-29 | 再開されました | Stephens | Overweight |
| 2021-02-10 | 開始されました | Piper Sandler | Overweight |
| 2020-05-21 | 開始されました | Raymond James | Outperform |
| 2019-01-04 | 開始されました | Oppenheimer | Outperform |
| 2018-02-12 | 繰り返されました | B. Riley FBR, Inc. | Buy |
| 2018-02-09 | 繰り返されました | Chardan Capital Markets | Buy |
| 2017-12-08 | 開始されました | B. Riley FBR, Inc. | Buy |
| 2017-06-12 | 開始されました | Chardan Capital Markets | Buy |
| 2017-06-06 | 開始されました | Ladenburg Thalmann | Buy |
| 2016-06-30 | 開始されました | Rodman & Renshaw | Buy |
すべてを表示
Gyre Therapeutics Inc (GYRE) 最新ニュース
Will Gyre Therapeutics Inc stock hit new highs in YEAR2026 Spike Watch & Risk Controlled Swing Trade Alerts - baoquankhu1.vn
Pulmatrix shares dive as privately-held pharma company chooses to merge with Gyre Therapeutics instead - MSN
Gyre Therapeutics (GYRE) to Release Earnings on Tuesday - MarketBeat
Gyre Therapeutics Submits NDA for F351 (Hydronidone) to China CDE for Treatment of Chronic Hepatitis B-Induced Liver Fibrosis - Minichart
Gyre Therapeutics Files NDA in China for F351 - TipRanks
Gyre Therapeutics (GYRE) submits China NDA for Hydronidone in CHB liver fibrosis - Stock Titan
EV Market: What are analysts price targets for Gyre Therapeutics Inc2026 Drop Watch & Daily Stock Momentum Reports - baoquankhu1.vn
Zacks Research Downgrades Gyre Therapeutics (NASDAQ:GYRE) to Strong Sell - MarketBeat
Gyre Therapeutics (NASDAQ:GYRE) Trading Down 8.2%Time to Sell? - MarketBeat
China grants priority review to Gyre’s liver fibrosis drug By Investing.com - Investing.com India
China grants priority review to Gyre’s liver fibrosis drug - Investing.com
Gyre Therapeutics Announces China's NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment - Bitget
Aug Intraday: Is Gyre Therapeutics Inc currently under institutional pressureTrade Ideas & Weekly Top Gainers Alerts - baoquankhu1.vn
Gyre Therapeutics Announces China’s NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment - The Manila Times
Gyre Therapeutics, Inc. Announces China?s NMPA Grants Priority Review to the NDA for Hydronidone for CHB-Induced Liver Fibrosis Treatment - marketscreener.com
Gyre Therapeutics Faces Operational Risk From Rapid Shifts in Clinical Demand and Market Conditions - The Globe and Mail
Gyre Therapeutics Forms Golden Cross, Signaling Potential Bullish Breakout - Markets Mojo
Gyre Therapeutics (NASDAQ:GYRE) Announces Earnings Results - MarketBeat
Analysts Offer Insights on Healthcare Companies: OptimizeRx (OPRX) and Gyre Therapeutics (GYRE) - The Globe and Mail
Gyre Therapeutics (NASDAQ:GYRE) Downgraded by Wall Street Zen to Hold - MarketBeat
Gyre Therapeutics 2025 10-K: Revenue $116.6M, Net Income Per Share Decline - TradingView
Gyre Therapeutics (NASDAQ: GYRE) grows China fibrosis base, eyes Hydronidone NDAs - Stock Titan
Analysts Are Bullish on These Healthcare Stocks: Indivior (INDV), Gyre Therapeutics (GYRE) - The Globe and Mail
Gyre Therapeutics Stock (ISIN: KYG4200L1031) Faces Pressure After Q4 Earnings Miss Amid Pipeline Mom - AD HOC NEWS
Gyre Therapeutics Sees Stable $100 Million Lung Fibrosis Drug Revenue - marketscreener.com
Volatility Watch: Whats Gyre Therapeutics Incs historical returnTrade Performance Summary & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
GNI Group Highlights Fibrosis Revenue Upside and Advances Degrader Pipeline via Gyre and Cullgen - TipRanks
Gyre Therapeutics (GYRE) Q4 Loss Challenges Bullish Margin Durability Narratives - simplywall.st
Gyre Therapeutics, Inc. (GYRE) Q4 earnings miss estimates - MSN
Gyre Therapeutics (NASDAQ:GYRE) Shares Gap DownShould You Sell? - MarketBeat
Gyre Therapeutics (GYRE) Posts Q4 FY25 Loss of $0.02; misses estimates - AlphaStreet
Gyre Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2025 - marketscreener.com
Gyre Therapeutics, Inc. (GYRE) Q4 Results Fall Short of Expectations - Bitget
Gyre Therapeutics Projects Strong Growth for Fibrosis Programs - TipRanks
Gyre Therapeutics, Inc. (GYRE) Q4 Earnings Miss Estimates - Yahoo Finance
Gyre Therapeutics, Inc. Provides Revenues Outlook for 2026 - marketscreener.com
GYRE | Gyre Therapeutics, Inc. Common FinancialsIncome Statement - Quiver Quantitative
Gyre Therapeutics Q4 revenue beats estimates on new product launch - TradingView
Gyre Therapeutics Swings to Net Loss in Q4, Revenue Increases - marketscreener.com
Gyre Therapeutics (NASDAQ: GYRE) details F351, ETUARY and CG001419 outlook at investor conference - Stock Titan
Gyre Therapeutics reports fourth quarter and full year 2025 financial results - marketscreener.com
(GYRE) Gyre Therapeutics Expects 2026 Revenue Range $100.5M to $111.0M, vs. FactSet Est of $148.0M - marketscreener.com
Earnings Flash (GYRE) Gyre Therapeutics Posts Q4 Revenue $37.2M, vs. FactSet Est of $35.4M - marketscreener.com
Earnings Flash (GYRE) Gyre Therapeutics Posts Q4 Loss $0.02 a Share, vs. FactSet Est of $0.06 EPS - marketscreener.com
Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - The Manila Times
Gyre Therapeutics Reports 10% Revenue Growth in Full-Year 2025 and Announces Acquisition of Cullgen - Quiver Quantitative
Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides ... - Caledonian Record
Biotech Gyre to add $300M degrader drug pipeline in 2026 deal - Stock Titan
Gyre Therapeutics (NASDAQ: GYRE) grows 2025 revenue but guides 2026 decline - Stock Titan
Gyre Therapeutics (GYRE) Expected to Announce Quarterly Earnings on Monday - MarketBeat
Earnings Update: Can Gyre Therapeutics Inc maintain its current growth rateJuly 2025 Momentum & Stepwise Trade Signal Guides - baoquankhu1.vn
Gyre Therapeutics Inc (GYRE) 財務データ
収益
当期純利益
現金流量
EPS
1.82%
大文字化:
|
ボリューム (24 時間):